Atara Biotherapeutics (NASDAQ:ATRA) Upgraded by Canaccord Genuity Group to “Strong-Buy” Rating

Canaccord Genuity Group upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a hold rating to a strong-buy rating in a report released on Friday morning,Zacks.com reports.

A number of other research firms also recently weighed in on ATRA. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Atara Biotherapeutics in a research note on Friday, March 27th. New Street Research set a $6.00 price objective on Atara Biotherapeutics in a report on Tuesday, January 13th. Finally, Wall Street Zen lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Atara Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

Atara Biotherapeutics Trading Down 16.0%

Shares of NASDAQ ATRA opened at $8.34 on Friday. Atara Biotherapeutics has a one year low of $3.92 and a one year high of $19.15. The firm has a market capitalization of $70.97 million, a PE ratio of 2.67 and a beta of -0.30. The business has a 50-day moving average price of $5.25 and a two-hundred day moving average price of $9.32.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.43. Atara Biotherapeutics had a negative return on equity of 79.12% and a net margin of 27.07%.The firm had revenue of $1.60 million during the quarter, compared to analyst estimates of $0.70 million. Research analysts anticipate that Atara Biotherapeutics will post 0.2 EPS for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. acquired a new position in Atara Biotherapeutics during the second quarter worth $31,000. Dimensional Fund Advisors LP acquired a new position in Atara Biotherapeutics during the fourth quarter worth $181,000. Walleye Capital LLC acquired a new position in Atara Biotherapeutics during the fourth quarter worth $220,000. Marshall Wace LLP acquired a new position in Atara Biotherapeutics during the second quarter worth $327,000. Finally, Quadrature Capital Ltd increased its position in Atara Biotherapeutics by 22.8% during the fourth quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock worth $368,000 after buying an additional 3,779 shares during the last quarter. Institutional investors and hedge funds own 70.90% of the company’s stock.

Key Headlines Impacting Atara Biotherapeutics

Here are the key news stories impacting Atara Biotherapeutics this week:

• Positive Sentiment: Atara said its FDA discussions on tabelecleucel keep the resubmission/regulatory pathway open, easing fears that the therapy had been permanently derailed. Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
• Positive Sentiment: Market commentary highlighted that ATRA surged after the FDA meeting, indicating investors viewed the update as better-than-feared for the company’s lead cell-therapy program. Atara surges after FDA meeting on cell therapy
• Neutral Sentiment: Several law firms issued notices and deadline reminders about a securities class action tied to purchases between May 20, 2024 and January 9, 2026; these updates add uncertainty but are largely procedural at this stage. ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
• Neutral Sentiment: Additional class-action notices from Gross, Rosen, Faruqi, Bronstein, and Pomerantz reinforce the legal backdrop, but they do not appear to be the primary driver of the day’s move versus the FDA update. Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
• Negative Sentiment: The ongoing securities-fraud lawsuit and repeated lead-plaintiff reminders signal potential legal costs and reputational risk for Atara Biotherapeutics. ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATRA

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.